Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
英文全名
Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
英文别名
Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin
蛋白结构
氨基酸序列
MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F
Accession
Gene ID
产品英文概述
The clinical use of the potent antitumor activity of TNF-alphahas been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-alphamutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-alpha, which binds to the murine TNF-R55 but not to the murine TNF-R75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-alpha, which binds to both murine TNF receptors. Based on these results, many TNF-alphamutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.
来源
Escherichia coli.
分子量
Approximately 16.9 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, rHuTNF-α Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo.
生物活性
Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg in the presence of actinomycin D.
外观
Sterile filtered white lyophilized (freeze-dried) powder.
配方
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0.
内毒素
Less than 1 EU/ug of rHu TNF-α/TNFSF2, Variant as determined by LAL method.
溶解说明
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
参考资料
纯度
> 98 % by SDS-PAGE and HPLC analyses.
SDS-PAGE电泳
包装规格
10ug/100ug/500ug
安全数据表下载 (SDS)
技术参数表下载 (TDS)
品牌链接
Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant是ChemWhat品牌授权产品并通过沃尔森销售，下面是ChemWhat上的该产品链接 Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
